EvolutionaryScale, a startup founded by former Meta employees, has introduced the AI model ESM3 capable of generating new proteins, achieving advancements that mimic natural evolution in a fraction of the time. Trained on a vast dataset of 2.78 billion proteins, ESM3 is positioned to revolutionize biology by enabling the engineering of proteins for various applications like drug discovery. The company secured $142 million in seed funding, with support from industry leaders like Nat Friedman, AWS, and NVIDIA, emphasizing the significant potential of AI in biotech. EvolutionaryScale's innovative approach to making biology programmable through AI models has garnered attention and investment, showcasing the growing intersection of AI and biology for transformative advancements in healthcare and environmental solutions.